swisspartners Ltd. purchased a new stake in PerkinElmer, Inc. (NYSE:PKI) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,813 shares of the medical research company’s stock, valued at approximately $233,000.
A number of other institutional investors have also recently added to or reduced their stakes in PKI. Select Equity Group L.P. raised its holdings in PerkinElmer by 11.0% in the fourth quarter. Select Equity Group L.P. now owns 10,326,036 shares of the medical research company’s stock worth $1,481,786,000 after purchasing an additional 1,019,219 shares during the period. BlackRock Inc. increased its holdings in shares of PerkinElmer by 7.6% in the first quarter. BlackRock Inc. now owns 7,904,659 shares of the medical research company’s stock worth $1,014,091,000 after acquiring an additional 556,072 shares in the last quarter. Ceredex Value Advisors LLC raised its position in shares of PerkinElmer by 0.4% during the first quarter. Ceredex Value Advisors LLC now owns 1,251,337 shares of the medical research company’s stock worth $160,534,000 after purchasing an additional 5,287 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of PerkinElmer by 7.5% in the first quarter. The Manufacturers Life Insurance Company now owns 1,163,843 shares of the medical research company’s stock valued at $149,310,000 after buying an additional 81,506 shares during the period. Finally, Norges Bank bought a new stake in shares of PerkinElmer during the fourth quarter worth $142,590,000. 92.74% of the stock is currently owned by institutional investors and hedge funds.
PKI stock traded down $0.11 during trading hours on Friday, reaching $146.00. 3,740 shares of the stock were exchanged, compared to its average volume of 961,229. The firm’s 50-day simple moving average is $137.57. PerkinElmer, Inc. has a 12 month low of $93.23 and a 12 month high of $162.70. The company has a market cap of $16.37 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 0.40 and a beta of 1.12. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.41 and a current ratio of 1.76.
The firm also recently announced a quarterly dividend, which will be paid on Friday, August 6th. Investors of record on Friday, July 16th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.19%. The ex-dividend date is Thursday, July 15th. PerkinElmer’s payout ratio is 3.37%.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Read More: What is a SEC Filing?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.